The Hartford Financial Services Group, Inc. DEB FIX/FLT 42 (HGH) Stock Competitors & Peer Comparison
See (HGH) competitors and their performances in Stock Market.
Peer Comparison Table: Insurance - Diversified Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HGH | $25.01 | +0.02% | 0 | -3.09 | -$8.08 | N/A |
| BRK-A | $733,550.00 | +2.11% | 1.1T | 14.56 | $50,386.68 | N/A |
| BRK-B | $488.13 | +1.98% | 1.1T | 14.52 | $33.61 | N/A |
| AIG-PA | $62.68 | +6.02% | 112.5B | 5.48 | $11.44 | +2.39% |
| AEH | $25.67 | +0.00% | 52.5B | 19.37 | $1.33 | +5.26% |
| AED | $25.52 | +0.00% | 52.2B | 19.26 | $1.33 | +5.26% |
| AEB | $25.01 | -0.08% | 51.1B | 18.88 | $1.33 | +5.26% |
| SLF | $73.72 | +1.04% | 40.9B | 19.00 | $3.88 | +3.61% |
| AIG | $75.49 | +2.79% | 40B | 13.29 | $5.68 | +2.39% |
| ACGL | $91.19 | +3.23% | 31.9B | 7.01 | $13.00 | N/A |
Stock Comparison
HGH vs BRK-A Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, BRK-A has a market cap of 1.1T. Regarding current trading prices, HGH is priced at $25.01, while BRK-A trades at $733,550.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas BRK-A's P/E ratio is 14.56. In terms of profitability, HGH's ROE is +0.02%, compared to BRK-A's ROE of +0.10%. Regarding short-term risk, HGH is less volatile compared to BRK-A. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check BRK-A's competition here
HGH vs BRK-B Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, BRK-B has a market cap of 1.1T. Regarding current trading prices, HGH is priced at $25.01, while BRK-B trades at $488.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas BRK-B's P/E ratio is 14.52. In terms of profitability, HGH's ROE is +0.02%, compared to BRK-B's ROE of +0.10%. Regarding short-term risk, HGH is less volatile compared to BRK-B. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check BRK-B's competition here
HGH vs AIG-PA Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, AIG-PA has a market cap of 112.5B. Regarding current trading prices, HGH is priced at $25.01, while AIG-PA trades at $62.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas AIG-PA's P/E ratio is 5.48. In terms of profitability, HGH's ROE is +0.02%, compared to AIG-PA's ROE of +0.08%. Regarding short-term risk, HGH is less volatile compared to AIG-PA. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check AIG-PA's competition here
HGH vs AEH Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, AEH has a market cap of 52.5B. Regarding current trading prices, HGH is priced at $25.01, while AEH trades at $25.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas AEH's P/E ratio is 19.37. In terms of profitability, HGH's ROE is +0.02%, compared to AEH's ROE of +0.12%. Regarding short-term risk, HGH is less volatile compared to AEH. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check AEH's competition here
HGH vs AED Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, AED has a market cap of 52.2B. Regarding current trading prices, HGH is priced at $25.01, while AED trades at $25.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas AED's P/E ratio is 19.26. In terms of profitability, HGH's ROE is +0.02%, compared to AED's ROE of +0.12%. Regarding short-term risk, HGH is less volatile compared to AED. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check AED's competition here
HGH vs AEB Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, AEB has a market cap of 51.1B. Regarding current trading prices, HGH is priced at $25.01, while AEB trades at $25.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas AEB's P/E ratio is 18.88. In terms of profitability, HGH's ROE is +0.02%, compared to AEB's ROE of +0.12%. Regarding short-term risk, HGH is less volatile compared to AEB. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check AEB's competition here
HGH vs SLF Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, SLF has a market cap of 40.9B. Regarding current trading prices, HGH is priced at $25.01, while SLF trades at $73.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas SLF's P/E ratio is 19.00. In terms of profitability, HGH's ROE is +0.02%, compared to SLF's ROE of +0.13%. Regarding short-term risk, HGH is less volatile compared to SLF. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check SLF's competition here
HGH vs AIG Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, AIG has a market cap of 40B. Regarding current trading prices, HGH is priced at $25.01, while AIG trades at $75.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas AIG's P/E ratio is 13.29. In terms of profitability, HGH's ROE is +0.02%, compared to AIG's ROE of +0.08%. Regarding short-term risk, HGH is less volatile compared to AIG. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check AIG's competition here
HGH vs ACGL Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ACGL has a market cap of 31.9B. Regarding current trading prices, HGH is priced at $25.01, while ACGL trades at $91.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ACGL's P/E ratio is 7.01. In terms of profitability, HGH's ROE is +0.02%, compared to ACGL's ROE of +0.20%. Regarding short-term risk, HGH is less volatile compared to ACGL. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ACGL's competition here
HGH vs ATH Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ATH has a market cap of 19.8B. Regarding current trading prices, HGH is priced at $25.01, while ATH trades at $83.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ATH's P/E ratio is 4.42. In terms of profitability, HGH's ROE is +0.02%, compared to ATH's ROE of +0.00%. Regarding short-term risk, HGH is less volatile compared to ATH. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ATH's competition here
HGH vs ACGLP Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ACGLP has a market cap of 15.2B. Regarding current trading prices, HGH is priced at $25.01, while ACGLP trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ACGLP's P/E ratio is 5.03. In terms of profitability, HGH's ROE is +0.02%, compared to ACGLP's ROE of +0.20%. Regarding short-term risk, HGH is less volatile compared to ACGLP. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ACGLP's competition here
HGH vs BNT Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, BNT has a market cap of 14.8B. Regarding current trading prices, HGH is priced at $25.01, while BNT trades at $44.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas BNT's P/E ratio is 16.26. In terms of profitability, HGH's ROE is +0.02%, compared to BNT's ROE of +0.03%. Regarding short-term risk, HGH is less volatile compared to BNT. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check BNT's competition here
HGH vs AEG Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, AEG has a market cap of 12.4B. Regarding current trading prices, HGH is priced at $25.01, while AEG trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas AEG's P/E ratio is 11.76. In terms of profitability, HGH's ROE is +0.02%, compared to AEG's ROE of +0.12%. Regarding short-term risk, HGH is less volatile compared to AEG. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check AEG's competition here
HGH vs EQH Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, EQH has a market cap of 11.5B. Regarding current trading prices, HGH is priced at $25.01, while EQH trades at $40.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas EQH's P/E ratio is -14.32. In terms of profitability, HGH's ROE is +0.02%, compared to EQH's ROE of -2.20%. Regarding short-term risk, HGH is less volatile compared to EQH. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check EQH's competition here
HGH vs ACGLO Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ACGLO has a market cap of 11.4B. Regarding current trading prices, HGH is priced at $25.01, while ACGLO trades at $19.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ACGLO's P/E ratio is 4.15. In terms of profitability, HGH's ROE is +0.02%, compared to ACGLO's ROE of +0.20%. Regarding short-term risk, HGH is less volatile compared to ACGLO. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ACGLO's competition here
HGH vs ORI Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ORI has a market cap of 9.3B. Regarding current trading prices, HGH is priced at $25.01, while ORI trades at $38.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ORI's P/E ratio is 9.40. In terms of profitability, HGH's ROE is +0.02%, compared to ORI's ROE of +0.17%. Regarding short-term risk, HGH is less volatile compared to ORI. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ORI's competition here
HGH vs ACGLN Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ACGLN has a market cap of 5.9B. Regarding current trading prices, HGH is priced at $25.01, while ACGLN trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ACGLN's P/E ratio is 3.49. In terms of profitability, HGH's ROE is +0.02%, compared to ACGLN's ROE of +0.20%. Regarding short-term risk, HGH is less volatile compared to ACGLN. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ACGLN's competition here
HGH vs EQH-PA Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, EQH-PA has a market cap of 5.6B. Regarding current trading prices, HGH is priced at $25.01, while EQH-PA trades at $19.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas EQH-PA's P/E ratio is 5.09. In terms of profitability, HGH's ROE is +0.02%, compared to EQH-PA's ROE of -2.20%. Regarding short-term risk, HGH is less volatile compared to EQH-PA. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check EQH-PA's competition here
HGH vs ESGRP Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ESGRP has a market cap of 5.3B. Regarding current trading prices, HGH is priced at $25.01, while ESGRP trades at $20.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ESGRP's P/E ratio is -13.72. In terms of profitability, HGH's ROE is +0.02%, compared to ESGRP's ROE of +0.03%. Regarding short-term risk, HGH and ESGRP have similar daily volatility (0.00).Check ESGRP's competition here
HGH vs ATH-PE Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ATH-PE has a market cap of 5.2B. Regarding current trading prices, HGH is priced at $25.01, while ATH-PE trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ATH-PE's P/E ratio is N/A. In terms of profitability, HGH's ROE is +0.02%, compared to ATH-PE's ROE of +0.00%. Regarding short-term risk, HGH is less volatile compared to ATH-PE. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ATH-PE's competition here
HGH vs ATH-PC Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ATH-PC has a market cap of 5.1B. Regarding current trading prices, HGH is priced at $25.01, while ATH-PC trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ATH-PC's P/E ratio is 3.14. In terms of profitability, HGH's ROE is +0.02%, compared to ATH-PC's ROE of +0.00%. Regarding short-term risk, HGH is less volatile compared to ATH-PC. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ATH-PC's competition here
HGH vs UNMA Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, UNMA has a market cap of 5B. Regarding current trading prices, HGH is priced at $25.01, while UNMA trades at $22.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas UNMA's P/E ratio is 4.63. In terms of profitability, HGH's ROE is +0.02%, compared to UNMA's ROE of +0.07%. Regarding short-term risk, HGH is less volatile compared to UNMA. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check UNMA's competition here
HGH vs ESGR Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ESGR has a market cap of 5B. Regarding current trading prices, HGH is priced at $25.01, while ESGR trades at $337.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ESGR's P/E ratio is 10.83. In terms of profitability, HGH's ROE is +0.02%, compared to ESGR's ROE of +0.03%. Regarding short-term risk, HGH and ESGR have similar daily volatility (0.00).Check ESGR's competition here
HGH vs ESGRO Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ESGRO has a market cap of 5B. Regarding current trading prices, HGH is priced at $25.01, while ESGRO trades at $19.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ESGRO's P/E ratio is -12.87. In terms of profitability, HGH's ROE is +0.02%, compared to ESGRO's ROE of +0.03%. Regarding short-term risk, HGH and ESGRO have similar daily volatility (0.00).Check ESGRO's competition here
HGH vs ATH-PA Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ATH-PA has a market cap of 4.9B. Regarding current trading prices, HGH is priced at $25.01, while ATH-PA trades at $24.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ATH-PA's P/E ratio is 3.09. In terms of profitability, HGH's ROE is +0.02%, compared to ATH-PA's ROE of +0.00%. Regarding short-term risk, HGH is less volatile compared to ATH-PA. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ATH-PA's competition here
HGH vs EQH-PC Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, EQH-PC has a market cap of 4.7B. Regarding current trading prices, HGH is priced at $25.01, while EQH-PC trades at $16.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas EQH-PC's P/E ratio is 4.20. In terms of profitability, HGH's ROE is +0.02%, compared to EQH-PC's ROE of -2.20%. Regarding short-term risk, HGH is less volatile compared to EQH-PC. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check EQH-PC's competition here
HGH vs ATH-PB Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ATH-PB has a market cap of 3.9B. Regarding current trading prices, HGH is priced at $25.01, while ATH-PB trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ATH-PB's P/E ratio is 2.38. In terms of profitability, HGH's ROE is +0.02%, compared to ATH-PB's ROE of +0.00%. Regarding short-term risk, HGH is less volatile compared to ATH-PB. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ATH-PB's competition here
HGH vs ATH-PD Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ATH-PD has a market cap of 3.3B. Regarding current trading prices, HGH is priced at $25.01, while ATH-PD trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ATH-PD's P/E ratio is 2.04. In terms of profitability, HGH's ROE is +0.02%, compared to ATH-PD's ROE of +0.00%. Regarding short-term risk, HGH is less volatile compared to ATH-PD. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ATH-PD's competition here
HGH vs CNO-PA Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, CNO-PA has a market cap of 3.1B. Regarding current trading prices, HGH is priced at $25.01, while CNO-PA trades at $17.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas CNO-PA's P/E ratio is N/A. In terms of profitability, HGH's ROE is +0.02%, compared to CNO-PA's ROE of +0.10%. Regarding short-term risk, HGH is less volatile compared to CNO-PA. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check CNO-PA's competition here
HGH vs FIHL Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, FIHL has a market cap of 2.4B. Regarding current trading prices, HGH is priced at $25.01, while FIHL trades at $23.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas FIHL's P/E ratio is 10.93. In terms of profitability, HGH's ROE is +0.02%, compared to FIHL's ROE of +0.16%. Regarding short-term risk, HGH is less volatile compared to FIHL. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check FIHL's competition here
HGH vs PLGO Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, PLGO has a market cap of 1.9B. Regarding current trading prices, HGH is priced at $25.01, while PLGO trades at $21.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas PLGO's P/E ratio is 5.99. In terms of profitability, HGH's ROE is +0.02%, compared to PLGO's ROE of +0.16%. Regarding short-term risk, HGH is less volatile compared to PLGO. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check PLGO's competition here
HGH vs RZC Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, RZC has a market cap of 1.7B. Regarding current trading prices, HGH is priced at $25.01, while RZC trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas RZC's P/E ratio is N/A. In terms of profitability, HGH's ROE is +0.02%, compared to RZC's ROE of +0.09%. Regarding short-term risk, HGH is less volatile compared to RZC. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check RZC's competition here
HGH vs GSHD Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, GSHD has a market cap of 1.5B. Regarding current trading prices, HGH is priced at $25.01, while GSHD trades at $38.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas GSHD's P/E ratio is 33.64. In terms of profitability, HGH's ROE is +0.02%, compared to GSHD's ROE of -0.30%. Regarding short-term risk, HGH is less volatile compared to GSHD. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check GSHD's competition here
HGH vs XZO Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, XZO has a market cap of 1.2B. Regarding current trading prices, HGH is priced at $25.01, while XZO trades at $13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas XZO's P/E ratio is 14.04. In terms of profitability, HGH's ROE is +0.02%, compared to XZO's ROE of +0.42%. Regarding short-term risk, HGH is less volatile compared to XZO. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check XZO's competition here
HGH vs IGIC Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, IGIC has a market cap of 1.1B. Regarding current trading prices, HGH is priced at $25.01, while IGIC trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas IGIC's P/E ratio is 9.18. In terms of profitability, HGH's ROE is +0.02%, compared to IGIC's ROE of +0.18%. Regarding short-term risk, HGH is less volatile compared to IGIC. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check IGIC's competition here
HGH vs AIZN Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, AIZN has a market cap of 945.3M. Regarding current trading prices, HGH is priced at $25.01, while AIZN trades at $19.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas AIZN's P/E ratio is N/A. In terms of profitability, HGH's ROE is +0.02%, compared to AIZN's ROE of +0.17%. Regarding short-term risk, HGH is less volatile compared to AIZN. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check AIZN's competition here
HGH vs ARGD Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ARGD has a market cap of 874.2M. Regarding current trading prices, HGH is priced at $25.01, while ARGD trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ARGD's P/E ratio is N/A. In terms of profitability, HGH's ROE is +0.02%, compared to ARGD's ROE of +0.02%. Regarding short-term risk, HGH is less volatile compared to ARGD. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ARGD's competition here
HGH vs WDH Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, WDH has a market cap of 513.6M. Regarding current trading prices, HGH is priced at $25.01, while WDH trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas WDH's P/E ratio is 6.45. In terms of profitability, HGH's ROE is +0.02%, compared to WDH's ROE of +0.11%. Regarding short-term risk, HGH is less volatile compared to WDH. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check WDH's competition here
HGH vs KWY Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, KWY has a market cap of 293.8M. Regarding current trading prices, HGH is priced at $25.01, while KWY trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas KWY's P/E ratio is -25.37. In terms of profitability, HGH's ROE is +0.02%, compared to KWY's ROE of N/A. Regarding short-term risk, HGH is less volatile compared to KWY. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check KWY's competition here
HGH vs YB Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, YB has a market cap of 112.6M. Regarding current trading prices, HGH is priced at $25.01, while YB trades at $14.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas YB's P/E ratio is 3.62. In terms of profitability, HGH's ROE is +0.02%, compared to YB's ROE of +0.66%. Regarding short-term risk, HGH is less volatile compared to YB. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check YB's competition here
HGH vs FGFPP Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, FGFPP has a market cap of 25.9M. Regarding current trading prices, HGH is priced at $25.01, while FGFPP trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas FGFPP's P/E ratio is -7.69. In terms of profitability, HGH's ROE is +0.02%, compared to FGFPP's ROE of -0.72%. Regarding short-term risk, HGH is less volatile compared to FGFPP. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check FGFPP's competition here
HGH vs WTREP Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, WTREP has a market cap of 0. Regarding current trading prices, HGH is priced at $25.01, while WTREP trades at $25.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas WTREP's P/E ratio is 1.35. In terms of profitability, HGH's ROE is +0.02%, compared to WTREP's ROE of +0.00%. Regarding short-term risk, HGH is less volatile compared to WTREP. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check WTREP's competition here
HGH vs ANAT Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, ANAT has a market cap of 0. Regarding current trading prices, HGH is priced at $25.01, while ANAT trades at $188.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas ANAT's P/E ratio is 6.73. In terms of profitability, HGH's ROE is +0.02%, compared to ANAT's ROE of +0.10%. Regarding short-term risk, HGH is less volatile compared to ANAT. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check ANAT's competition here
HGH vs AMIC Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, AMIC has a market cap of 0. Regarding current trading prices, HGH is priced at $25.01, while AMIC trades at $24.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas AMIC's P/E ratio is N/A. In terms of profitability, HGH's ROE is +0.02%, compared to AMIC's ROE of +0.04%. Regarding short-term risk, HGH is less volatile compared to AMIC. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check AMIC's competition here
HGH vs IGICW Comparison June 2026
HGH plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HGH stands at 0. In comparison, IGICW has a market cap of 0. Regarding current trading prices, HGH is priced at $25.01, while IGICW trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HGH currently has a P/E ratio of -3.09, whereas IGICW's P/E ratio is N/A. In terms of profitability, HGH's ROE is +0.02%, compared to IGICW's ROE of +0.18%. Regarding short-term risk, HGH is less volatile compared to IGICW. This indicates potentially lower risk in terms of short-term price fluctuations for HGH.Check IGICW's competition here